PLTR
Palantir
-- 76.070 TSLA
Tesla
-- 436.230 NVDA
NVIDIA
-- 134.250 MSTR
MicroStrategy
-- 408.670 AVGO
Broadcom
-- 224.800 
NEWS TODAY
Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer
EDAP TMS SA (Nasdaq: EDAP) announced the publication of the HIFI study results in European Urology, comparing Focal One® Robotic HIFU to radical prostatectomy (RP) for localized prostate cancer treatment. The landmark study, involving 3,328 patients across 46 centers, demonstrated that Focal One Robotic HIFU is non-inferior to surgery for Salvage Treatment-free Survival at 30 months.
Key findings show that the HIFU arm achieved 90% adjusted STFS compared to 86% in the RP arm. HIFU patients experienced significantly better outcomes in urinary continence (29% vs 44% deterioration) and erectile function. These superior functional results were achieved despite HIFU patients being approximately 9.6 years older than RP patients (median age 74.7 vs 65.1 years).
Key findings show that the HIFU arm achieved 90% adjusted STFS compared to 86% in the RP arm. HIFU patients experienced significantly better outcomes in urinary continence (29% vs 44% deterioration) and erectile function. These superior functional results were achieved despite HIFU patients being approximately 9.6 years older than RP patients (median age 74.7 vs 65.1 years).
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment